Mizon P, Jouet J P, Vanhaesbroucke C, Villard F, Wibaut B, Goudemand J
Laboratoire d'Hématologie du CHRU de Lille.
Transfus Clin Biol. 1994;1(4):271-7. doi: 10.1016/s1246-7820(94)80014-6.
Direct antiglobulin test (DAT), ABO typing and isoagglutinins titers were regularly performed in 26 patients who received a marrow transplant from a major ABO incompatible donor (M = 10 cases), from a minor ABO incompatible donor (m = 10 cases) or both (B = 6 cases). Erythrocyte or plasma depletion of bone marrow infusate was used in all major or certain minor ABO incompatibilities respectively. A positive DAT was recorded in 19/26 patients at various times, but only a few of them, belonging to groups M or B, exhibited a significant hemolysis. No serious complication was observed after bone marrow infusion. Five patients showed evidence of hemolysis after transplantation, 1 patient died with a graft rejection and 3 patients had a delayed erythropoietic engraftment. In all cases of major ABO incompatibility, the erythrocyte recovery was preceeded by a decrease of antibodies against the donor's blood group. These antibodies finally disappeared in all patients except one who had a persistence of isoagglutinins beyond day + 650. A transient appearance of isoagglutinins against the recipient blood group was sometimes detected in minor ABO incompatibility without any clinical complications.
对26例接受来自主要ABO血型不相合供者(M组 = 10例)、次要ABO血型不相合供者(m组 = 10例)或二者均不相合供者(B组 = 6例)骨髓移植的患者定期进行直接抗球蛋白试验(DAT)、ABO血型鉴定和同种凝集素滴度检测。对于所有主要ABO血型不相合或某些次要ABO血型不相合的情况,分别对骨髓输注物进行红细胞或血浆去除处理。26例患者中有19例在不同时间记录到DAT阳性,但其中只有少数属于M组或B组的患者出现明显溶血。骨髓输注后未观察到严重并发症。5例患者移植后出现溶血迹象,1例患者死于移植物排斥,3例患者红细胞生成延迟植入。在所有主要ABO血型不相合的病例中,红细胞恢复之前针对供者血型的抗体水平下降。除1例患者在 + 650天之后仍持续存在同种凝集素外,这些抗体最终在所有患者中消失。在次要ABO血型不相合的情况下,有时会检测到针对受者血型的同种凝集素短暂出现,但无任何临床并发症。